Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, ...
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer ...
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal ...
Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel ...
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology ...
FDA grants accelerated approval to INOVIO’s Voceryq for reducing surgery frequency in adults with recurrent respiratory ...
Karyopharm filed for Chapter 11 under a plan to merge with Ayrmid, with competing bids allowed and closing targeted for the ...
Lonza will add bioconjugate, payload-linker and viral vector capacity and about 1,100 employees; closing is expected in mid-2027.
Dr. Jay Lalezari, CEO and CMO, CytoDyn, describes the transition from decades as a front-line HIV clinician to running a ...
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior ...
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, citing an internal portfolio decision unrelated to the platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results